Therefore, targeting the C5a/C5aR1–calcium–ACSL4 axis could effectively ameliorate fibrotic progression by reducing fibroblast activation and migration, potentially offering a novel therapeutic strategy for pulmonary fibrosis treatment. Here, C5AR1 is linked to pulmonary fibrosis.